<DOC>
	<DOCNO>NCT00087997</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness experimental study drug ( STA-4783 ) combine approved cancer medicine , paclitaxel , treatment soft tissue sarcoma . Paclitaxel ( TaxolÂ® ) approve use United States since 1992 .</brief_summary>
	<brief_title>A Study STA-4783 Combination With Weekly Paclitaxel Treatment Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description>STA-4783 taxane potentiator , enhance effect antitumor response paclitaxel . In attempt improve efficacy , paclitaxel sometimes used combination anticancer agent . When paclitaxel combine anticancer agent , although response rate usually increase , side effect usually increase well . There urgent need agent enhance antitumor effect paclitaxel without increase undesirable side effect .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Must 18 year age old histologic diagnosis soft tissue sarcoma Must disease suitable curative resection Must fail &gt; 1 first line treatment evidence progression . Adjuvant therapy count 1st line therapy unless recurrence occurs within 6 month administration Must ability understand willingness sign write informed consent document Must Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion At least 4 week pass since last chemotherapy , immunotherapy , radiation therapy There must measurable disease outside radiotherapy field progression indicator lesion within field since completion radiotherapy Must life expectancy great 12 week Must clinical laboratory value screen define : Hemoglobin &gt; 9 g/dL , Absolute neutrophil count &gt; 1500/mm3 , Platelet count &gt; 100,000/mm3 , Creatinine &lt; 1.5 X ULN , Bilirubin &lt; 1.5 X ULN , Asparate aminotransferase alanine aminotransferase &lt; 2.5 X ULN ( &lt; 5 X ULN presence liver metastasis ) Female patient pregnant breast feed Patients childbearing potential use willing use barrier method contraception Prior malignancy soft tissue sarcoma ( STS ) within last 5 yrs exception : Adequately treat situ carcinoma cervix uterus ; Basal squamous cell carcinoma skin Presence clinically significant uncontrolled infection Presence &gt; Grade 2 neuropathy Symptomatic central nervous system metastasis within last 8 week corticosteroid CNS symptom management Presence clinically significant arrythmias Presence serious concurrent illness condition ( e.g. , psychological , family , sociological , geographical circumstance ) permit adequate followup compliance protocol History severe hypersensitivity reaction taxanes cremaphore spite premedication Use investigational agent within 4 week prior first dose study drug ( ) Major surgery within 2 week screen Radiation treatment past &gt; 25 % bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>sarcoma</keyword>
</DOC>